Develop Tumor Treating Fields (TTFields) technology for cancer treatment. Manufacture and commercialize Optune for glioblastoma. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 87% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $655.4M a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 46 buys and 33 sells. Management buying with its own money is usually read as a good sign.
A loss of $136.2M against $655.4M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 23/100.
The growth engine is running at low revs right now. Report-card grade: 46/100.
On our five-subject report card, NVCR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NVCR has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (57/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.